CancerNetwork

Oncology On The Go

Oncology On The Go is a weekly podcast that talks to authors and experts to thoroughly examine featured articles in the journal ONCOLOGY and review other challenging treatment scenarios in the cancer field from a multidisciplinary perspective. Our discussions also offer timely insight into topics ranging from recent FDA approvals to relevant research presented at major oncology conferences. As the home of the journal ONCOLOGY, CancerNetwork offers different perspectives on oncology/hematology through review articles, news, podcasts, blogs, and more. To learn more, you can also visit us on Face...

Vizitează neapărat site-ul podcastului și susține-i creatorul: www.cancernetwork.com

Autor

CancerNetwork

Categorie

Science

Site-ul podcastului

www.cancernetwork.com

Cel mai nou episod

16 nov. 2026

Unde asculți?

Podcasturi în aplicație Replaio Radio În curând

Podcasturile ajung în curând în aplicație. Instaleaz-o acum și fii primul care descoperă o abordare complet nouă a podcasturilor

Descarcă din Google Play Instalează gratuit Android 10 mil.+ descărcări · nota 4,7+ iOS în curând

Episoade

S1 Ep218: Unraveling Key Hematologic Oncology Developments at ASCO 2026 08.06.2026

In a live X Spaces discussion hosted by CancerNetwork® in collaboration with the American Society for Transplantation and Cellular Therapy (ASTCT), Marc J. Braunstein, MD, PhD, and Sofia Zahid, MD, highlighted noteworthy presentations and abstracts in hematologic oncology at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. Together, they discussed the data that may shake up cl...

S1 Ep217: Integrating Exercise and Lifestyle Intervention Into Oncologic Therapy 01.06.2026

In a conversation with CancerNetwork®, Nathan Goodyear, MD , spoke about the role that exercise and lifestyle intervention can play in the treatment of patients with cancer. He described how prescribed exercise may serve as a biologically interventional therapy that can help prolong longevity, reduce the risk of recurrence; and supplement the efficacy of standard therapeutic approaches like chemot...

S1 Ep216: How the Landscape of GI Oncology is Evolving | A 2026 ASCO Preview 28.05.2026

In a recent interview with CancerNetwork®, Nicholas Hornstein, MD, PhD, an assistant professor at the Donald and Barbara Zucker School of Medicine of Hofstra University and Northwell Health, discussed emerging data and clinical shifts in the care of patients with gastrointestinal (GI) cancers ahead of the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting . Advancements in Colorectal...

S1 Ep215: Navigating The Dynamic Landscape of Stem Cell Transplantation 25.05.2026

In a cobranded episode between Oncology on the Go , hosted by CancerNetwork®, and the American Society for Transplantation and Cellular Therapy (ASTCT)’s program ASTCT Talks , Mitchell E. Horwitz, MD, highlighted key developments and ongoing initiatives related to allogeneic and cord blood transplantations among patients with different hematologic malignancies. The conversation touched upon the im...

S1 Ep214: Are Zedoresertib and Lunresertib an Efficacious Combo Across Solid Tumors? 18.05.2026

Results from the first-in-human, phase 1 MYTHIC trial (NCT04855656) demonstrated that combining the WEE1 inhibitor zedoresertib with the PYKMT1 inhibitor lunresertib achieved an overall response rate (ORR) of 18.5% via RECIST criteria in patients with CCNE1 , FBXW7 , and PPP2R1A -altered cancers.1 In patients with resistant/refractory ovarian cancer, the ORR was 33.3% across all dose levels and 50...

S1 Ep213: What Does the Future Hold for Immune Effector Cell Therapies? 11.05.2026

Following the 2026 National ICE-T Conference in Charlotte, North Carolina, Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, and Barry Paul, MD, spoke with CancerNetwork® about high-level takeaways that emerged during the meeting. They discussed how CAR T-cell therapies, bispecific antibodies, and other novel modalities currently fit into the treatment paradigm across multiple myeloma, leukemia, lymp...

S1 Ep212: Unraveling Daraxonrasib’s Breakthrough in Metastatic Pancreatic Cancer 04.05.2026

In a conversation with CancerNetwork®, Diane Simeone, MD, discussed the implications of daraxonrasib demonstrating meaningful improvements in survival among patients with metastatic pancreatic ductal adenocarcinoma (PDAC) in the phase 3 RASolute 302 trial (NCT06625320). Topline findings from the trial showed that the novel multiselective RAS(ON) inhibitor approximately doubled the median overall s...

S1 Ep211: Exploring and Managing Gastrointestinal-Related CAR T-Cell Lymphomas 27.04.2026

In a special cobranded episode between Oncology On the Go, hosted by CancerNetwork®, and the American Society for Transplantation and Cellular Therapy (ASTCT)’s program ASTCT Talks , host Rahul Banerjee, MD, FACP, spoke with colleague Hitomi Hosoya, MD, PhD, about a study she and coauthors published in Blood. In their study, Hosoya and colleagues assessed the underlying mechanisms of CAR T-cell–re...

S1 Ep210: Elevating Precision Medicine Across Different Oncologic Populations 20.04.2026

At the 3rd Biennial Miami Precision Medicine Conference, CancerNetwork® spoke with a variety of researchers and clinicians who presented on different topics regarding the use of targeted therapies across several cancer types. Faculty from the University of Miami Sylvester Comprehensive Cancer Center shared key advances and ongoing initiatives across pancreatic cancer, sarcomas, genitourinary malig...

S1 Ep209: Rising Incidence, Trial Enrollment, and Other Key Breast Cancer Challenges 13.04.2026

In a conversation with CancerNetwork®, Shari Goldfarb, MD spoke about key developments and challenges regarding the treatment of younger populations with breast cancer. Key areas across the field included the rising incidence of disease, including HER2-positive and triple-negative subtypes; expanding opportunities for clinical trial enrollment; and preserving fertility among patients undergoing tr...

S1 Ep208: Cancer and Suicide: Identifying Risk Factors and Providing Support 06.04.2026

In this episode recorded at the 2026 American Psychosocial Oncology Society (APOS) annual meeting, Daniel C. McFarland, DO, sat down with Kelly Irwin, MD, to address one of the most challenging topics in oncology: suicide risk. The conversation aimed to equip oncologists with the tools and confidence to navigate the emotional complexities of cancer care. Key Discussion Points: Understanding the Ri...

S1 Ep207: Providing Support for Mental Health Disorders Across Cancer Populations 30.03.2026

In a conversation with CancerNetwork®, Julian Hong, MD, MS, discussed considerations for optimizing care among patients with mental health disorders (MHDs) who are undergoing treatment for cancer. He spoke in the context of a study he and coauthors published in Cancer, which showed that patients with cancer and a mental health condition experience an increased risk of all-cause mortality. Specific...

S1 Ep206: Is It Helping or Harming? A Clinician’s Guide to Cannabis Use in Oncology 23.03.2026

In this episode of Oncology on The Go , created in collaboration with the American Psychosocial Oncology Society, Daniel C. McFarland, DO, and Ilana M. Braun, MD, dove into the complexities of cannabis use within the oncology landscape. They explored the tension between rising public popularity and the need for rigorous scientific scrutiny in symptom management. Key Discussion Points: The 2024 ASC...

S1 Ep205: Insights Across Hematologic Oncology at Columbia University 16.03.2026

During a visit to Columbia University Irving Cancer Research Center, experts across hematologic oncology shared their perspectives on key trends and developments in their respective fields. These conversations explored novel therapeutic approaches and translational research that may advance the paradigm across different leukemia, multiple myeloma, and lymphoma populations. First, Nicole Lamanna, M...

S1 Ep204: Unraveling the Potential of Iberdomide and CELMoDs in Multiple Myeloma 09.03.2026

In a conversation with CancerNetwork®, Sagar Lonial, MD, FACP, FASCO, discussed the potential implications of the FDA approving iberdomide plus daratumumab (Darzalex) and dexamethasone for patients with relapsed/refractory multiple myeloma. He spoke in context of the FDA accepting a new drug application for the iberdomide regimen based on data from the phase 3 EXCALIBER-RRMM trial (NCT04975997). L...

S1 Ep203: Navigating Depression in Cancer Care 02.03.2026

Daniel C. McFarland, DO, and Boris Kiselev, MD, highlighted the need for oncologists to recognize and address depression for patients with cancer.  In a new episode of Oncology on the Go created in collaboration with the American Psychosocial Oncology Society, host Daniel C. McFarland, DO, spoke with Boris Kiselev, MD. Together, they explored the complex intersection of oncology and psychiatry. Th...

S1 Ep202: From Cold to Hot: Navigating a New Frontier of Breast Cancer Immunotherapy 23.02.2026

Sarah Poland, MD, lead author of a recently published article in the journal ONCOLOGY titled Advances in Immunotherapy for Breast Cancer , highlighted key findings from her review in a conversation with CancerNetwork®.1 Throughout the discussion, she spoke about:  Shifting Perspectives on Immunogenicity : Historically, breast cancer was considered a “cold,” poorly immunogenic tumor due to low tumo...

S1 Ep201: What Were the Key Abstracts and Presentations at The 2026 Tandem Meetings? 16.02.2026

At the 2026 Tandem Meetings, CancerNetwork® spoke with a variety of experts who presented on key developments and advancements across hematologic oncology. As part of different oral presentations and poster sessions, researchers and clinicians shared updated findings that may influence the management of myelodysplastic syndromes (MDS), leukemia, lymphoma, and other blood cancer types. First, Ferna...

S1 Ep200: Exploring the Bone Marrow Microenvironment’s Influence on NDMM Trajectory 09.02.2026

In a conversation with CancerNetwork®, Manoj Bhasin, PhD, MS, spoke about findings from a study in which he and colleagues developed a single-cell atlas characterizing the dysregulation of the bone marrow immune microenvironment in newly diagnosed multiple myeloma. Findings published in Nature Cancer showed that the immune system has a broad, treatment-independent influence on outcomes in newly di...

S1 Ep199: How to Responsibly Use AI in Palliative Care and Hematologic Malignancies 02.02.2026

In a conversation with CancerNetwork®, Ram Prakash Thirugnanasambandam, MBBS, discussed the evolving roles that artificial intelligence (AI)–based tools may play in palliative care and the management of different hematologic malignancies. He spoke in the context of a publication he authored, The Role of Artificial Intelligence in Palliative Oncology: Zeroing in on Hematologic Malignancies, which w...

S1 Ep198: Innovation, Elevation, and Empowerment Through Integrative Care in Oncology 26.01.2026

Emphasizing the evidence-based nature of medicine, Nathan Goodyear, MD, explained that integrative oncology uses many of the same parameters and key clinical thresholds among patients undergoing treatment for a diagnosis of cancer that his conventional oncologist colleagues use. In this episode of Oncology on the Go , Goodyear, an integrative medicine physician at the Williams Cancer Institute, di...

S1 Ep197: How Can Bioimpedance Spectroscopy Help Detect Lymphedema Quicker? 19.01.2026

In a conversation with CancerNetwork®, Kandace P. McGuire, MD, and Paschalia Mountziaris, MD, PhD, highlighted the use of L-Dex bioimpedance spectroscopy as a method for detecting lymphedema earlier in patients who undergo surgery for breast cancer. The experts discussed seamlessly integrating this novel modality into standard vitals workflows and detailed other considerations for improving long-t...

S1 Ep196: Bolstering Outcomes and Building Bridges in Integrative Oncology Care 12.01.2026

In a conversation with CancerNetwork®, Nathan Goodyear, MD, provided an overview of how to implement integrative modalities that may effectively supplement standard-of-care oncologic therapies. Beyond the use of intravenous vitamin C and other flagship strategies at his institution, Goodyear addressed potential misconceptions and biases surrounding integrative oncology and discussed how to re-enga...

S1 Ep195: Advancing Research and Combatting Disparities in Pancreatic Cancer Care 05.01.2026

In a conversation with CancerNetwork®, Jose G. Trevino, II, MD, FACS, spoke about the current state of the pancreatic ductal adenocarcinoma (PDAC) paradigm as well as next steps for improving the prognosis of patients who present with this disease. Throughout the discussion, Trevino outlined the roles that surgical oncologists can play in disease management, the different demographic and socioecon...

S1 Ep194: What’s New in Hematology/Oncology? Discussing the 2025 ASH Annual Meeting 29.12.2025

After the 2025 American Society of Hematology (ASH) Annual Meeting had passed, the  data were out, and the hematologist/oncologists of the world had time to digest the practice changes that awaited them upon their returns home. Rahul Banerjee, MD, FACP, and Brooke Adams, PharmD, BCOP, took part in an X Spaces discussion hosted by CancerNetwork® in collaboration with The American Society for Transp...

Ascultă podcastul Oncology On The Go în Replaio

Radio și podcasturi într-o singură aplicație - gratuit și fără înregistrare. Instaleaz-o azi și nu rata lansarea

Descarcă din Google Play

Replaio nu este editorul podcasturilor; numele emisiunilor, coperțile și materialul audio aparțin autorilor lor și sunt distribuite prin fluxuri RSS publice